Inhibition of NADPH oxidase-dependent production of ROS in diabetes by a variety of PKC inhibitors suggests a regulatory role of PKC in hyperglycemia induced NADPH oxidase activity [40]. The gene discussed is FMO5; the disease is diabetes mellitus.